Progressively increased levels of Cer in patients with mild to moderate symptoms of AD suggest changes in the metabolism of Cer already at an early stages of the disease and supports SM and Cer as biomarkers of AD (He et al. 2010). Here, CBLN1 is linked to Alzheimer disease.